Risk factors: Hyperhomocysteinemia: A renal and cardiovascular risk factor?

Nature Reviews Nephrology

Volumn 6, Issue 12, 2010, Pages 695-696

  Zoccali, Carmine ^a   Jager, Kitty J ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN B COMPLEX;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERHOMOCYSTEINEMIA; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; VITAMIN B COMPLEX;

EID: 79955015049     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.142     Document Type: Article

References (9)

1. McCully, K. S. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin. Chem. Lab. Med. 43, 980-986 (2005).
2. Heinz, J. et al. B vitamins and the risk of total mortality and cardiovascular disease in end- stage renal disease: results of a randomized controlled trial. Circulation 121, 1432-1438 (2010).
3. House, A. A. et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603-1609 (2010).
4. Kluijtmans, L. A. et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBs genotype on biochemical and clinical phenotype and on response to treatment. Am. J. Hum. Genet. 65, 59-67 (1999).
5. Wald, D. S., Law, M. & Morris, J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).
6. Wald, D. S., Wald, N. J., Morris, J. K. & Law, M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333, 1114-1117 (2006).
7. Zoungas, S. et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J.Am. Coll. Cardiol. 47, 1108-1116 (2006).
8. Bonaa, K. H. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354, 1578-1588 (2006).
9. de Jager, D. J. et al. Cardiovascular and non- cardiovascular mortality among patients initiating dialysis. JAMA 302, 1782-1789 (2009).